NY-FIRST-EAGLE-INV-MGMT
3.8.2020 12:02:05 CEST | Business Wire | Press release
First Eagle Investment Management, LLC (“First Eagle”) is pleased to announce plans to open a branch of First Eagle Investment Management Ltd. in Munich, Germany, through which the firm will serve international wholesale clients in Europe, the Middle East and Africa (EMEA) as well as in other non-US domiciles. The Munich office will be overseen by Matthieu Louanges, who joins First Eagle on August 3 as head of its international wholesale business. Louanges will be stationed in Munich in preparation for the official opening of First Eagle’s office there, expected in late 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005114/en/
“First Eagle traces its origin to Germany, and we are excited to reestablish our local presence there after an absence of more than 80 years,” said Mehdi Mahmud, President and Chief Executive Officer of First Eagle. “Arnhold and S. Bleichroeder, the predecessor firm to First Eagle, represented the amalgamation of two storied German banks: Berlin-based S. Bleichroeder, founded in 1803, and Dresden-based Gebr. Arnhold, founded in 1864. First Eagle’s European roots run deep, and the plan to open an office in continental Europe feels like something of a homecoming. Under the leadership of Matthieu, who has extensive experience working with international clients and building and managing multinational franchises, our Munich location will help us strengthen our partnership with Amundi Asset Management and enhance our client service outreach for non-US clients worldwide.”
Louanges and his team, located in Munich and New York, will be responsible for First Eagle’s international wholesale distribution business, which includes the firm’s distribution partnership with Amundi Asset Management. The European Union and the European continent will continue to be key elements of First Eagle’s international business, and the firm expects Asia and South America to be particularly important regions of business growth moving forward. Highlighting the firm’s commitment to its international business, Louanges will report to Mahmud and will join First Eagle’s Management Committee, marking the first time a Management Committee member has been based outside of the US.
French/German binational Louanges joins First Eagle after more than 20 years at PIMCO, where he was one of the most senior leaders in PIMCO’s EMEA franchise; as Managing Director, he most recently headed up the firm’s global relationship with Allianz. Earlier in his PIMCO tenure, Louanges launched the company’s EMEA insurance channel, which over time evolved into the broader financial institutions group, and he had broad oversight responsibility for PIMCO’s business in Switzerland and France as well as its EMEA client solutions team. Louanges joined PIMCO as a portfolio manager of mutual funds and institutional mandates in 2000 upon its acquisition by Allianz, where he had been playing a similar role.
“I am excited to join First Eagle Investment Management and become a member of its Management Committee,” said Louanges. “While First Eagle’s investment proposition already has a broad client base globally, given the increasingly uncertain economic and market environment, there remains a strong appetite for solutions that combine the potential for attractive returns with downside protection over full market cycles. I look forward to working closely with Mehdi and the rest of my new colleagues to make First Eagle’s time-tested, differentiated investments solutions accessible to international clients and to support our important partnership with Amundi Asset Management.”
Louanges succeeds Robert H. Hackney, Jr., a 25-year veteran of First Eagle. Hackney will remain with the firm, first to assist in the transition of his leadership of the international wholesale distribution business to Louanges and afterward as an advisor to Mahmud and the firm’s leadership team on strategic initiatives. “Robert’s leadership has been integral to the success of our partnership with Amundi Asset Management and our international wholesale business. We have benefited from his keen strategic perspective over the years, and I look forward to his ongoing counsel as we continue to evolve the firm,” said Mahmud.
ABOUT FIRST EAGLE INVESTMENT MANAGEMENT
First Eagle Investment Management is an independent, privately owned investment management firm headquartered in New York with approximately $101 billion in assets under management as of June 30, 2020. Dedicated to providing prudent stewardship of client assets, the firm focuses on active, fundamental and benchmark-agnostic investing, with a strong emphasis on downside protection. Over a long history dating back to 1864, First Eagle has helped its clients avoid permanent impairment of capital and earn attractive returns through widely varied economic cycles—a tradition that is central to its mission today. The firm’s investment capabilities include equity, fixed income, alternative credit and multi-asset strategies. For more information on First Eagle, please visit www.feim.com . For information on First Eagle Alternative Credit, please visit www.feac.com .
First Eagle Investment Management is the brand name for First Eagle Investment Management, LLC and its subsidiary investment advisers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
